Tidewave Bio Completes FDA INTERACT Meeting for TBC-1, a Universal Cell Therapy Platform in Solid TumorsLOS ANGELES, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tidewave Bio, a biotechnology company developing a universal, off-the-shelf, gene-enhanced antigen-presenting cell therapy platform, today announced the successful completion of its FDA INTERACT meeting. This milestone provides critical regulatory feedback as the company advances its lead program, TBC-1, toward IND-enabling studies.
